Thiogenesis Therapeutics

Executive Summary

Thiogenesis Therapeutics is a private biotechnology company based in Cambridge, MA, specializing in targeted protein degradation for genetically defined diseases. Founded in 2021, the company has developed a proprietary thiogenesis platform that leverages the body's natural degradation machinery to selectively eliminate disease-causing proteins. With a team of 50–200 employees, the company is at the platform stage, focusing on building a pipeline of therapies for rare genetic disorders where traditional small molecules or biologics have limited efficacy. The technology holds promise for addressing undruggable targets, potentially offering a new treatment paradigm for patients with high unmet medical needs. Thiogenesis operates in the competitive but rapidly evolving field of protein degradation, which has attracted significant interest from both academia and pharma. The company's ability to differentiate its platform through superior specificity, bioavailability, or manufacturing efficiency will be critical to its success.

Upcoming Catalysts (preview)

• Q2 2027Lead candidate nomination for lead program65% success
• Q1 2027Series A financing completion80% success
• Q4 2026Preclinical proof-of-concept data disclosure70% success